BioLineRx (BLRX) Interest Expenses (2013 - 2025)
BioLineRx (BLRX) posted Interest Expenses of -$280000.0 for Q4 2025, up 7.89% on a QoQ basis from -$304000.0 in Q3 2025, and up 93.75% year-over-year from -$144516.1 in Q4 2024.
BioLineRx (BLRX) has 13 years of Interest Expenses data on file, last reported at -$280000.0 in Q4 2025.
- In Q4 2025, Interest Expenses rose 93.75% year-over-year to -$280000.0; the TTM figure through Dec 2025 stood at -$1.3 million (up 85.96% YoY), while the FY2025 annual figure was -$1.3 million, up 85.96% from the prior year.
- Interest Expenses advanced to -$280000.0 in Q4 2025, from -$304000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $932000.0 in Q4 2023 and bottomed at -$4.5 million in Q4 2024.
- A 5-year average of -$833400.0 and a median of -$341500.0 in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses tumbled 1008.82% — and 2023, when it soared 141.2%.
- Year by year, Interest Expenses stood at -$204000.0 in 2021, then tumbled by 1008.82% to -$2.3 million in 2022, then soared by 141.2% to $932000.0 in 2023, then sank by 580.69% to -$4.5 million in 2024, then jumped by 93.75% to -$280000.0 in 2025.
- The last three Interest Expenses figures came in at -$280000.0 (Q4 2025), -$304000.0 (Q3 2025), and -$276000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 69.29 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | -280,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -280,000.00 |
| Dec 31, 2025 | -280,000.00 |
| Sep 30, 2025 | -304,000.00 |
| Sep 30, 2025 | -304,000.00 |
| Jun 30, 2025 | -276,000.00 |
| Jun 30, 2025 | -276,000.00 |
| Mar 31, 2025 | -420,000.00 |
| Mar 31, 2025 | -420,000.00 |
| Dec 31, 2024 | -4.48 Mn |
| Dec 31, 2024 | -4.48 Mn |
| Sep 30, 2024 | -1.63 Mn |
| Sep 30, 2024 | -1.63 Mn |
| Jun 30, 2024 | -2.09 Mn |
| Jun 30, 2024 | -2.09 Mn |
| Mar 31, 2024 | -929,000.00 |
| Mar 31, 2024 | -929,000.00 |
| Dec 31, 2023 | -4.34 Mn |
| Dec 31, 2023 | -4.34 Mn |
| Sep 30, 2023 | -837,000.00 |
| Sep 30, 2023 | -837,000.00 |
| Jun 30, 2023 | -1.34 Mn |
| Jun 30, 2023 | -1.34 Mn |
| Mar 31, 2023 | 630,000.00 |
| Mar 31, 2023 | 630,000.00 |
| Dec 31, 2022 | -1.33 Mn |
| Dec 31, 2022 | -1.33 Mn |
| Sep 30, 2022 | -267,000.00 |
| Sep 30, 2022 | -267,000.00 |
| Jun 30, 2022 | -379,000.00 |
| Jun 30, 2022 | -379,000.00 |
| Mar 31, 2022 | -186,000.00 |
| Mar 31, 2022 | -186,000.00 |
| Dec 31, 2021 | -204,000.00 |
| Dec 31, 2021 | -204,000.00 |
| Sep 30, 2021 | -261,000.00 |
| Sep 30, 2021 | -261,000.00 |
| Jun 30, 2021 | -242,000.00 |
| Jun 30, 2021 | -242,000.00 |
| Mar 31, 2021 | -299,000.00 |
| Mar 31, 2021 | -299,000.00 |
| Dec 31, 2020 | -517,000.00 |
| Dec 31, 2020 | -517,000.00 |
| Sep 30, 2020 | -302,000.00 |
| Sep 30, 2020 | -302,000.00 |
| Jun 30, 2020 | -396,000.00 |
| Jun 30, 2020 | -396,000.00 |
| Mar 31, 2020 | -414,000.00 |
| Mar 31, 2020 | -414,000.00 |
| Dec 31, 2019 | -793,000.00 |
| Dec 31, 2019 | -793,000.00 |
| Sep 30, 2019 | -597,000.00 |
| Sep 30, 2019 | -597,000.00 |
| Jun 30, 2019 | -440,000.00 |
| Jun 30, 2019 | -440,000.00 |
| Mar 31, 2019 | -447,000.00 |
| Mar 31, 2019 | -447,000.00 |
| Dec 31, 2018 | -327,000.00 |
| Dec 31, 2018 | -327,000.00 |
| Sep 30, 2018 | -11,000.00 |
| Sep 30, 2018 | -11,000.00 |
| Jun 30, 2018 | -11,000.00 |
| Jun 30, 2018 | -11,000.00 |
| Mar 31, 2018 | -206,000.00 |
| Mar 31, 2018 | -206,000.00 |
| Dec 31, 2017 | -6,000.00 |
| Dec 31, 2017 | -6,000.00 |
| Sep 30, 2017 | -6,000.00 |
| Sep 30, 2017 | -6,000.00 |
| Jun 30, 2017 | -3,000.00 |
| Jun 30, 2017 | -3,000.00 |
| Mar 31, 2017 | -6,000.00 |
| Mar 31, 2017 | -6,000.00 |
| Dec 31, 2016 | -10,000.00 |
| Dec 31, 2016 | -10,000.00 |
| Sep 30, 2016 | -4,000.00 |
| Sep 30, 2016 | -4,000.00 |
| Jun 30, 2016 | -5,000.00 |
| Jun 30, 2016 | -5,000.00 |
| Mar 31, 2016 | -4,000.00 |
| Mar 31, 2016 | -4,000.00 |
| Dec 31, 2015 | 5,000.00 |
| Dec 31, 2015 | 5,000.00 |
| Sep 30, 2015 | -91,000.00 |
| Sep 30, 2015 | -91,000.00 |
| Jun 30, 2015 | -2,000.00 |
| Jun 30, 2015 | -2,000.00 |
| Mar 31, 2015 | -17,000.00 |
| Mar 31, 2015 | -17,000.00 |
| Dec 31, 2014 | -62,000.00 |
| Dec 31, 2014 | -62,000.00 |
| Sep 30, 2014 | -303,000.00 |
| Sep 30, 2014 | -303,000.00 |
| Jun 30, 2014 | -435,000.00 |
| Jun 30, 2014 | -435,000.00 |
| Mar 31, 2014 | -81,000.00 |
| Mar 31, 2014 | -81,000.00 |
| Dec 31, 2013 | -286,000.00 |
| Dec 31, 2013 | -286,000.00 |
| Sep 30, 2013 | -553,000.00 |
| Sep 30, 2013 | -553,000.00 |
| Jun 30, 2013 | -473,000.00 |
| Jun 30, 2013 | -473,000.00 |
| Mar 31, 2013 | -556,000.00 |
| Mar 31, 2013 | -556,000.00 |